The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Health related quality of life (HRQoL) outcomes from the phase III CANDOR study comparing carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients (Pts) with relapsed or refractory multiple myeloma.
 
David Samuel DiCapua Siegel
Stock and Other Ownership Interests - Celularity
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen Oncology; Karyopharm Therapeutics; Merck; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene; Janssen Oncology; Takeda
Research Funding - Celgene (Inst)
 
Katja Weisel
Honoraria - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Sanofi; Takeda
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Sanofi; Takeda
Research Funding - Amgen (Inst); Celgene (Inst); Janssen (Inst); Sanofi (Inst)
 
Anita Zahlten-Kumeli
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Rohan Medhekar
Employment - Amgen
 
Sandhya Sapra
Employment - Amgen
 
Bifeng Ding
Employment - Amgen
 
Xavier Leleu
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; CARsgen Therapeutics; Celgene; Janssen-Cilag; Karyopharm Therapeutics; Merck; Mundipharma; Novartis; Oncopeptides; Pierre Fabre; Roche; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; CARsgen Therapeutics; Celgene; Gilead Sciences; Janssen-Cilag; Karyopharm Therapeutics; Merck; Mundipharma; Novartis; Oncopeptides; Roche; Takeda
Travel, Accommodations, Expenses - Takeda